相关实验视频

Updated: Jun 14, 2025

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

阿菲卡门对心声图心脏结构和功能的影响在症状阻塞性多变性心肌病的症状

Sheila M Hegde¹, Brian L Claggett¹, Xiaowen Wang¹

¹Brigham and Women's Hospital, Boston, Massachusetts, USA.

Journal of the American College of Cardiology

|September 1, 2024

概括

在患有阻塞性多变性心肌病 (oHCM) 的患者中,Aficamten显著改善了心脏功能,并减少了外流阻塞. 心声测量结果显示,腹功能和LVOT梯度有所改善,没有任何不良的缩功能变化.

科学领域:

心脏病学心脏病学
药理学药理学是指药理学的学科.
生物医学工程生物医学工程

背景情况:

阿菲卡门特是一种新型心脏肌酸酶抑制剂,用于症状性阻塞性多动性心肌病 (oHCM).
在SEQUOIA-HCM试验中,评估了aficamten在患有oHCM的成年人中的疗效和安全性.

研究的目的:

评估aficamten对心脏结构和功能的心声测量效果的影响.
评估左心室外流通道 (LVOT) 梯度和左心室喷射率 (LVEF) 的变化.

主要方法:

282名患有oHCM的患者在28周内随机分配给阿菲卡门特或安慰剂.
阿菲卡门的剂量被定位至每天20毫克,并连续进行心声回声图.
左心室喷射分数 (LVEF) 和LVOT梯度是关键评估参数.

主要成果:

阿菲卡门显著减少了静止和瓦萨尔瓦的LVOT梯度 (P ≤ 0.001).
观察到左心房体积指数,腹转功能 (e',E/e') 和 LV 维度的改善.
观察到LVEF和LV全球环形菌株的适度,可逆性下降,保持在正常范围内.

结论:

在患有oHCM的患者中,Aficamten改善了LVOT梯度和扩张功能.
观察到的心脏功能改善与增强的运动能力 (pVO2),生活质量 (KCCQ-CSS) 和减少的NT-proBNP.
阿菲卡门特表现出良好的安全性,没有对LV缩功能产生显著的不良影响.

关键词:

在LVOT梯度梯度下,一个有趣的东西.腹痛功能腹痛功能过度缩性心肌病变性心脏病.

更多相关视频

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation

Published on: July 20, 2022

相关概念视频

Pathophysiology of Heart Failure

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Imbalances in Cardiac Output

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...

Pathophysiology of Cardiac Performance

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...